Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
- Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profile
- On track to file IND[i] application to US FDA in Q1 2023
- Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of DSR 2.0, planned for Q2 2023
Ghent, Belgium – 01 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces positive results from its Phase 1 single-center, single-arm, single-dose trial (CHIHUAHUA) with its second-generation DSR product (DSR 2.0).